REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 154 filers reported holding REATA PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $12,910,685 | +20.0% | 126,625 | +7.0% | 0.03% | +13.0% |
| Q1 2023 | $10,762,655 | +299.5% | 118,375 | +66.9% | 0.02% | +283.3% |
| Q4 2022 | $2,694,061 | +37.2% | 70,915 | -9.2% | 0.01% | +20.0% |
| Q3 2022 | $1,963,000 | +2.9% | 78,115 | +24.5% | 0.01% | 0.0% |
| Q2 2022 | $1,907,000 | +171.7% | 62,736 | +192.8% | 0.01% | +400.0% |
| Q1 2022 | $702,000 | +303.4% | 21,427 | +225.6% | 0.00% | – |
| Q4 2021 | $174,000 | -89.0% | 6,580 | -41.3% | 0.00% | -100.0% |
| Q2 2021 | $1,587,000 | +602.2% | 11,218 | +394.0% | 0.00% | – |
| Q1 2021 | $226,000 | -19.6% | 2,271 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $281,000 | -70.1% | 2,271 | -76.4% | 0.00% | -50.0% |
| Q3 2020 | $939,000 | +108.7% | 9,643 | +234.4% | 0.00% | +100.0% |
| Q2 2020 | $450,000 | +34.3% | 2,884 | +24.1% | 0.00% | 0.0% |
| Q1 2020 | $335,000 | -45.7% | 2,324 | -22.9% | 0.00% | -50.0% |
| Q4 2019 | $617,000 | – | 3,014 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 2,896,901 | $291,457,000 | 32.14% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 46,646 | $4,693,000 | 5.31% |
| Ikarian Capital, LLC | 471,400 | $47,423,000 | 3.34% |
| Duquesne Family Office | 695,033 | $69,927,000 | 2.27% |
| Camber Capital Management LP | 685,000 | $68,918,000 | 2.12% |
| LBJ Family Wealth Advisors, Ltd. | 30,359 | $3,054,000 | 1.82% |
| MADDEN SECURITIES Corp | 33,127 | $3,333,000 | 1.80% |
| Biondo Investment Advisors, LLC | 104,120 | $10,475,000 | 1.80% |
| Tolleson Wealth Management, Inc. | 60,750 | $6,112,000 | 1.73% |
| Keel Point, LLC | 97,074 | $9,767,000 | 1.26% |